Jean‐Jacques Parienti

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015 · 965 citations

Medicine, Pathology, Pleural Disease +5

Intravascular Complications of Central Venous Catheterization by Insertion Site

Jean‐Jacques Parienti, Nicolas Mongardon, Bruno Mégarbane et al. · New England Journal of Medicine · 2015 · 744 citations · Full text

Femoral vs Jugular Venous Catheterization and Risk of Nosocomial Events in Adults Requiring Acute Renal Replacement Therapy

Jean‐Jacques Parienti, Marina Thirion, Bruno Mégarbane et al. · JAMA · 2008 · 418 citations

First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera: head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study

Denis Agostini, Vincent Roule, Catherine Nganoa et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 232 citations · Full text

Predictors of Virologic Failure and Resistance in HIV-Infected Patients Treated with Nevirapine- or Efavirenz-Based Antiretroviral Therapy

Jean‐Jacques Parienti, V. Massari, Diane Descamps et al. · Clinical Infectious Diseases · 2004 · 225 citations · Full text

Pharmacotherapy, Antiviral Drug, Efavirenz-based Antiretroviral Therapy +17